Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Advanced Lung Cancer
- Sponsor
- Hunan Province Tumor Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Progression-Free-Survival
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).
Investigators
Yongchang Zhang
Professor, Deputy Director of Thoracic Oncology Department
Hunan Province Tumor Hospital
Eligibility Criteria
Inclusion Criteria
- •Patients must be ≥18 years of age.
- •Provision of fully informed consent prior to any study specific procedures.
- •Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC.
- •Genetic variants of tumor tissue detected by NGS.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Progression-Free-Survival
Time Frame: Assessed up to around 4.5 years
From the time the first patient included in the observational analysis received treatment until disease progression, death due to various causes or censored at the date of last contact
Overall Survival
Time Frame: Assessed up to around 4.5 years
From the time the first patient included in the observational analysis received treatment until death due to various causes or censored at the date of last contact
Secondary Outcomes
- ORR(Assessed up to around 4.5 years)
- Clinical relevance between genomic profiling and overall survival(Assessed up to around 4.5 years)
- Clinical relevance between genomic profiling and progression-free-survival(Assessed up to around 4.5 years)